Early access
Sign in
Taking people in United StatesPhase 2

VIM0423 for adults living with isolated dystonia

Tests VIM0423 against a placebo in adults with isolated dystonia.

Key facts

Who runs it
Vima Therapeutics
Where
Albuquerque, Amherst, Atlanta, Aurora, Baltimore, Birmingham, Boston, Charleston, Chicago, Cincinnati, Dallas, Denver, East Lansing, Farmington Hills, Fayetteville, Gainesville, Georgetown, Houston, Irvine, Kirkland, Los Angeles, Memphis, Miami, Nashville, New York, Olney, Orlando, Overland Park, Philadelphia, Portland, Richmond, Rochester, Sacramento, Scottsdale, Spokane, St Louis, Sun City, and Vernon, United StatesSee the 41 sitesAlso in 1 other country, 4 sites
Trial code
Registry title
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
5 Feb 2026
Expected to end
May 2027
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • VIM0423
  • VIM0423 Placebo
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with isolated dystonia affecting two or more body regions. It tests VIM0423 against a placebo (a dummy drug).

Age
18 to 70 years
Sex
Men, and women who are not pregnant
Disease stage
Isolated dystonia with symptoms for at least one year, in two or more body regions (segmental, multifocal or generalized). The diagnosis must be confirmed by the study doctor and an enrollment committee. Symptom scores on the BFM and CGI-S scales must reach levels set by the protocol.
Earlier treatment
People who never had BoNT (botulinum toxin) can join. People who get BoNT as standard care can join if they meet criteria set by the protocol.

Main reasons for not taking part

  • Pregnant women cannot join.
  • Dystonia in only one body region.
  • Symptoms for less than one year.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participant must be male or nonpregnant female between 18 and 70 years of age (inclusive) at Visit 1 (Screening)
  • The participant has a clinical diagnosis of isolated dystonia with symptoms consistent with dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee
  • The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria
  • The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

Also in 1 other country, 4 sites

  • Albuquerque, New MexicoHospital not named in the registryContact: Study DirectorTaking people
  • Amherst, New YorkHospital not named in the registryContact: Study DirectorNot yet recruiting
  • Atlanta, GeorgiaHospital not named in the registryContact: Study DirectorTaking people
  • Aurora, ColoradoHospital not named in the registryContact: Study DirectorNot yet recruiting
  • Baltimore, MarylandHospital not named in the registryContact: Study DirectorTaking people
  • Birmingham, AlabamaHospital not named in the registryContact: Study DirectorTaking people
  • Boston, MassachusettsHospital not named in the registryContact: Study DirectorTaking people
  • Charleston, South CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Chicago, IllinoisHospital not named in the registryContact: Study DirectorTaking people
  • Cincinnati, OhioHospital not named in the registryContact: Study DirectorTaking people
  • Dallas, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Denver, ColoradoHospital not named in the registryContact: Study DirectorTaking people
  • East Lansing, MichiganHospital not named in the registryContact: Study DirectorTaking people
  • Farmington Hills, MichiganHospital not named in the registryContact: Study DirectorTaking people
  • Fayetteville, North CarolinaHospital not named in the registryContact: Study DirectorTaking people
  • Gainesville, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Georgetown, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Houston, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Houston, TexasHospital not named in the registryContact: Study DirectorTaking people
  • Irvine, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Kirkland, WashingtonHospital not named in the registryContact: Study DirectorTaking people
  • Los Angeles, CaliforniaHospital not named in the registryContact: Study DirectorTaking people
  • Memphis, TennesseeHospital not named in the registryContact: Study DirectorTaking people
  • Miami, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Nashville, TennesseeHospital not named in the registryContact: Study DirectorTaking people
  • New YorkHospital not named in the registryContact: Study DirectorTaking people
  • New YorkHospital not named in the registryContact: Study DirectorTaking people
  • Olney, MarylandHospital not named in the registryContact: Study DirectorTaking people
  • Orlando, FloridaHospital not named in the registryContact: Study DirectorTaking people
  • Overland Park, KansasHospital not named in the registryContact: Study DirectorTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: Study DirectorTaking people
  • Portland, OregonHospital not named in the registryContact: Study DirectorTaking people
  • Richmond, VirginiaHospital not named in the registryContact: Study DirectorTaking people
  • Rochester, New YorkHospital not named in the registryContact: Study DirectorTaking people
  • Sacramento, CaliforniaHospital not named in the registryContact: Study DirectorNot yet recruiting
  • Scottsdale, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Scottsdale, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Spokane, WashingtonHospital not named in the registryContact: Study DirectorTaking people
  • St Louis, MissouriHospital not named in the registryContact: Study DirectorTaking people
  • Sun City, ArizonaHospital not named in the registryContact: Study DirectorTaking people
  • Vernon, ConnecticutHospital not named in the registryContact: Study DirectorNot yet recruiting

About the trial

What the trial wants to find out

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.

Read full original descriptionShow less

The main objectives of this clinical trial are to determine the following:

* Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

The 4 groups in the trial

  • Segmental/multifocal ActiveExisting treatment, for comparison

    Segmental/Multifocal isolated dystonia (enrolling participants with at least two body parts affected receiving active n\~40

    Treatment: VIM0423

  • Segmental/multifocal PlaceboPlacebo, for comparison

    Segmental/Multifocal isolated dystonia (enrolling participants with at least two body parts affected) receiving placebo n\~40

    Treatment: VIM0423 Placebo

  • Generalized ActiveExisting treatment, for comparison

    Generalized isolated dystonia (enrolling participants with more than two body parts affected) receiving active n\~10

    Treatment: VIM0423

  • Generalized PlaceboPlacebo, for comparison

    Generalized isolated dystonia (enrolling participants with more than two body parts affected) receiving placebo n\~10

    Treatment: VIM0423 Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)
Plain-language title
VIM0423 for adults living with isolated dystoniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07304089, who can take part
Record updated
26 October 2026